A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Must have received: immunomodulatory drug

Received 1 to 3 prior lines of antimyeloma therapy, including an immunomodulatory drug (IMiD) and an anti-cluster of differentiation 38 (CD38) monoclonal antibody (mAb). A minimum of 2 consecutive cycles of an IMiD ... is required.

Must have received: anti-CD38 monoclonal antibody

Received 1 to 3 prior lines of antimyeloma therapy, including an immunomodulatory drug (IMiD) and an anti-cluster of differentiation 38 (CD38) monoclonal antibody (mAb). A minimum of 2 consecutive cycles of ... an anti-CD38 mAb ... is required.

Cannot have received: BCMA-targeted therapy

Prior B-cell maturation antigen (BCMA)-targeted therapy

Cannot have received: T-cell engager therapy

Prior T-cell engager therapy

Cannot have received: CAR-T cell therapy

Prior CAR therapy or other genetically modified T-cell therapy

Cannot have received: autologous stem cell transplant

Exception: within 12 weeks before randomization

Prior auto-SCT within 12 weeks before randomization

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant (allo-SCT)